HeLa human cervical cancer cells and mouse neuroblastoma × rat glioma cells were purchased from American Type Cell Collection (ATCC). HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (GIBCO) supplemented with penicillin (100 units/mL), streptomycin (100 μg/mL), and 10% Fetalgro bovine growth serum (RMBIO). Human Sig-1R CRISPR/Cas9 knockout (KO) and Sig-1R HDR plasmids (Santa Cruz) were transiently co-transfected into HeLa cells with the Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific) and were cultured in Dulbecco’s modified Eagle’s medium (GIBCO), penicillin (100 units/mL), streptomycin (100 μg/mL), and 10% Fetalgro bovine growth serum (RMBIO). For the selection of stably transfected Sig-1R CRISPR/Cas9-KO cells, cells were maintained in culture media supplemented with puromycin (100 μg/mL, GIBCO) for stable cell lines selection to generate permanent HeLa-Sig-1R-KO cells. NG-108 cells were cultured in Eagle’s minimum essential medium (GIBCO) supplemented with penicillin (100 units/mL), streptomycin (100 μg/mL), and 10% Fetalgro bovine growth serum (RMBIO). All cell lines were kept at 37 °C in a humidified 5% CO2 incubator (Thermo Fisher Scientific).
+ Open protocol